| Literature DB >> 28862648 |
Chiung-Yao Huang1, Jui-Hsin Su2,3, Chih-Chuang Liaw4, Ping-Jyun Sung5,6, Pei-Lun Chiang7, Tsong-Long Hwang8,9,10, Chang-Feng Dai11, Jyh-Horng Sheu12,13,14,15.
Abstract
A continuing chemical investigation of the ethyl acetate (EtOAc) extract of a reef soft coral Sinularia brassica, which was cultured in a tank, afforded four new steroids with methyl ester groups, sinubrasones A-D (1-4) for the first time. In particular, 1 possesses a β-D-xylopyranose. The structures of the new compounds were elucidated on the basis of spectroscopic analyses. The cytotoxicities of compounds 1-4 against the proliferation of a limited panel of cancer cell lines were assayed. The anti-inflammatory activities of these new compounds 1-4 were also evaluated by measuring their ability to suppress superoxide anion generation and elastase release in N-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced human neutrophils. Compounds 2 and 3 were shown to exhibit significant cytotoxicity, and compounds 3 and 4 were also found to display attracting anti-inflammatory activities.Entities:
Keywords: Sinularia brassica; anti-inflammatory activity; cytotoxic activity; soft coral; steroid
Mesh:
Substances:
Year: 2017 PMID: 28862648 PMCID: PMC5618419 DOI: 10.3390/md15090280
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–4.
1H and 13C-NMR spectroscopic data of 1.
| 1 | |||||
|---|---|---|---|---|---|
| Position | Position | ||||
| 1 | 156.0, CH | 7.05 d (10.0) | 1′ | 104.5, CH | 4.30 d (7.0) |
| 2 | 127.5, CH | 6.23 d (10.0) | 2′ | 73.4, CH | 3.42 dd (8.5, 7.0) |
| 3 | 186.5, C | 3′ | 75.9, CH | 3.52 dd (8.5, 8.5) | |
| 4 | 123.8, CH | 6.07 s | 4′ | 69.5, CH | 3.75 ddd (9.5, 8.5, 5.0) |
| 5 | 169.3, C | 5′ | 64.9, CH2 | 4.01 dd (12.0, 5.0); | |
| 6 | 32.8, CH2 | 2.47 ddd (12.5, 12.5, 4.5) | 3.30 d (12.0, 9.5) | ||
| 2.36 br d (12.5) | 26-OMe | 52.1, CH3 | 3.71 s | ||
| 7 | 33.6, CH2 | 1.95 m; 1.04 m | |||
| 8 | 35.5, CH | 1.63 m | |||
| 9 | 52.3, CH | 1.04 m | |||
| 10 | 43.6, C | ||||
| 11 | 22.8, CH2 | 1.70 m | |||
| 12 | 39.4, CH2 | 2.04 m; 1.16 m | |||
| 13 | 43.0, C | ||||
| 14 | 55.0, CH | 0.99 m | |||
| 15 | 24.5, CH2 | 1.66 m; 1.20 m | |||
| 16 | 27.5, CH2 | 1.68 m; 1.34 m | |||
| 17 | 52.6, CH | 1.06 m | |||
| 18 | 11.9, CH3 | 0.76 s | |||
| 19 | 18.7, CH3 | 1.23 s | |||
| 20 | 39.5, CH | 2.04 m | |||
| 21 | 12.6, CH3 | 0.92 d (6.5) | |||
| 22 | 81.5, CH | 3.63 br d (11.0) | |||
| 23 | 32.3, CH2 | 1.43 ddd (14.5, 11.0, 3.5); | |||
| 1.28 m | |||||
| 24 | 31.5, CH | 2.29 m | |||
| 25 | 40.9, CH | 2.62 qd (6.0, 4.0) | |||
| 26 | 177.7, C | ||||
| 27 | 9.9, CH3 | 1.02 d (7.0) | |||
| 28 | 16.3, CH3 | 0.85 d (7.0) | |||
Spectrum recorded at 100 MHz in CDCl3. Attached protons were deduced by distortionless enhancement by polarization transfer (DEPT) experiment. Spectrum recorded at 500 MHz in CDCl3.
Figure 2Selected correlation spectroscopy (COSY) and heteronuclear multiple bond correlations (HMBC) of 1–4.
Figure 3Selected nuclear Overhauser effect (NOE) correlations for 1.
1H and 13C-NMR spectroscopic data of 2–4.
| 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|
| Position | ||||||
| 1 | 155.7, CH | 7.04 d (10.0) | 156.0, CH | 7.05 d (10.4) | 155.8, CH | 7.05 d (10.0) |
| 2 | 127.6, CH | 6.23 d (10.0) | 127.5, CH | 6.23 d (10.4) | 127.5, CH | 6.23 d (10.0) |
| 3 | 186.3, C | 186.5, C | 186.4, C | |||
| 4 | 123.9, CH | 6.07 s | 123.8, CH | 6.07 s | 123.9, CH | 6.07 s |
| 5 | 168.9, C | 169.4, C | 169.2, C | |||
| 6 | 32.7, CH2 | 2.46 ddd (12.0, 12.0, 4.0) | 32.9, CH2 | 2.47 m | 32.8, CH2 | 2.46 ddd (13.0, 13.0, 4.0) |
| 2.36 br d (12.0) | 2.37 m | 2.36 m | ||||
| 7 | 33.5, CH2 | 1.90 m; 1.07 m | 33.6, CH2 | 1.96 m; 1.05 m | 33.5, CH2 | 1.94 m; 1.05 m |
| 8 | 35.1, CH | 1.76 m | 35.5, CH | 1.60 m | 35.5, CH | 1.64 m |
| 9 | 52.2, CH | 1.09 m | 52.4, CH | 1.06 m | 52.2, CH | 1.08 m |
| 10 | 43.6, C | 43.6, C | 43.5, C | |||
| 11 | 22.4, CH2 | 1.69 m | 22.8, CH2 | 1.66 m | 22.8, CH2 | 1.71 m |
| 12 | 38.8, CH2 | 1.71 m | 39.3, CH2 | 1.99 m | 39.2, CH2 | 1.97 ddd (13.0, 3.0, 3.0) |
| 1.21 m | 1.21 m | 1.28 m | ||||
| 13 | 40.9, C | 43.0, C | 42.7, C | |||
| 14 | 54.6, CH | 1.36 dd (12.0, 5.5) | 55.0, CH | 1.02 m | 55.0, CH | 1.08 m |
| 15 | 33.5, CH2 | 1.96 dd (12.0, 5.5) | 24.6, CH2 | 1.63 m | 24.4, CH2 | 1.62 m |
| 1.31 dd (12.0, 12.0) | 1.17 m | 1.19 m | ||||
| 16 | 117.9, C | 26.9, CH2 | 1.93 m; 1.60 m | 27.0, CH2 | 1.70 m; 1.30 m | |
| 17 | 70.9, CH | 1.65 m | 55.8, CH | 1.30 m | 52.7, CH | 1.60 m |
| 18 | 15.3, CH3 | 0.83 s | 12.2, CH3 | 0.73 s | 12.2, CH3 | 0.76 s |
| 19 | 19.2, CH3 | 1.24 s | 18.7, CH3 | 1.23 s | 18.7, CH3 | 1.23 s |
| 20 | 38.1, CH | 1.74 m | 38.5, CH | 1.30 m | 42.4, CH | 2.43 m |
| 21 | 18.8, CH3 | 1.02 d (7.0) | 15.9, CH3 | 0.99 d (7.2) | 17.0, CH3 | 1.18 d (7.0) |
| 22 | 86.9, CH | 3.69 m | 63.9, CH | 2.59 dd (4.8, 2.4) | 177.1, C | |
| 23 | 38.5, CH2 | 1.53 m; 1.48 m | 59.1, CH | 2.52 dd (7.6, 2.4) | ||
| 24 | 33.3, CH | 2.07 dddq (6.5, 6.5, 6.5, 6.5) | 39.2, CH | 1.54 m | ||
| 25 | 43.6, CH | 2.49 dq (6.5, 6.5) | 42.9, CH | 2.48 m | ||
| 26 | 176.8, C | 175.6, C | ||||
| 27 | 11.9, CH3 | 1.08 d (6.5) | 14.5, CH3 | 1.21 d (7.2) | ||
| 28 | 16.3, CH3 | 0.93 d (6.5) | 14.8, CH3 | 1.02 d (7.2) | ||
| 16-OMe | 49.3, CH3 | 3.20 s | ||||
| 22-OMe | 51.4, CH3 | 3.65 s | ||||
| 26-OMe | 51.4, CH3 | 3.67 s | 51.5, CH3 | 3.69 s | ||
Spectrum recorded at 125 MHz in CDCl3. Attached protons were deduced by DEPT experiment. Spectrum recorded at 500 MHz in CDCl3. Spectrum recorded at 100 MHz in CDCl3. Spectrum recorded at 400 MHz in CDCl3.
Figure 4Selected NOE correlations for 2 and 3.
Cytotoxicity (IC50 μM) of compounds 1–4.
| Cell lines IC50 (μM) | ||||
|---|---|---|---|---|
| Compound | P388D1 | MOLT-4 | K-562 | HT-29 |
| 37.2 ± 4.0 | 37.8 ± 5.6 | ― | ― | |
| 9.7 ± 1.2 | 6.0 ± 0.4 | 5.2 ± 0.8 | 7.6 ± 2.3 | |
| 5.7 ± 1.8 | 5.3 ± 1.3 | 12.1 ± 2.4 | 10.4 ± 2.2 | |
| 24.4 ± 4.8 | 31.2 ± 7.0 | 21.3 ± 3.7 | 36.5 ± 7.9 | |
| 6.2 ± 0.7 | 6.9 ± 1.3 | 33.1 ± 8.9 | 7.7 ± 0.8 | |
Clinical anticancer drug used as a positive control. ―: IC50 > 40 μM.
Inhibitory (% Inh) effects of compounds 1–4 on superoxide anion generation and elastase release in fMLP/CB-induced human neutrophils at 10 μM.
| Compounds | Superoxide Anion | Elastase Release | ||||
|---|---|---|---|---|---|---|
| IC50 (μM) | Inh % | IC50 (μM) | Inh % | |||
| >10 | 24.8 ± 6.5 | * | >10 | 35.6 ± 1.3 | *** | |
| >10 | 19.4 ± 5.0 | * | >10 | 39.0 ± 2.3 | *** | |
| >10 | 27.7 ± 1.3 | *** | 6.6 ± 1.7 | 58.8 ± 4.0 | *** | |
| 8.4 ± 1.1 | 53.6 ± 1.8 | *** | 6.5 ± 1.1 | 66.3 ± 6.0 | *** | |
| 0.07 ± 0.01 | 102.8 ± 2.2 | *** | 0.3 ± 0.1 | 99.6 ± 4.2 | *** | |
Concentration necessary for 50% inhibition (IC50). Percentage of inhibition (Inh%) at 10 μM concentration. Results are presented as mean ± S.E.M. (n = 3–4). * p < 0.05, *** p < 0.001 compared with the control value.